Kazia Therapeutics Files June 2024 6-K Report

TL;DR

Kazia Therapeutics (KZA) filed its monthly 6-K, standard procedure for foreign issuers.

AI Summary

Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on June 24, 2024. The company, headquartered in Sydney, NSW, is a pharmaceutical preparations company. This filing is for the month of June 2024 and indicates the company files annual reports under Form 20-F.

Why It Matters

This filing provides routine updates for investors and regulatory bodies regarding Kazia Therapeutics' ongoing reporting obligations as a foreign private issuer.

Risk Assessment

Risk Level: low — This filing is a routine report and does not contain new material financial or operational information that would typically increase risk.

Key Players & Entities

• Kazia Therapeutics Limited (company) — Registrant
• Novogen Ltd (company) — Former company name
• 20240624 (date) — Filing date
• June 2024 (date) — Reporting period
• Sydney NSW (location) — Company headquarters

FAQ

Key Financial Figures

• $150,000 — cordas annual base compensation will be $150,000. Mr. Bonacorda joined Kazia on May 13

Filing Documents

• d860441d6k.htm (6-K) — 9KB
• 0001193125-24-166929.txt ( ) — 10KB

From the Filing

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrants name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-FForm 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): INFORMATION CONTAINED IN THIS FORM 6-K REPORT Appointment of Director Resignation of Principal Financial and Accounting Officer; Appointment of Principal Accounting Officer and Principal Financial Officer On May 16, 2024, Kazia Therapeutics Limited (the Company) received notice from Gabrielle Heaton of her intention to resign as the Companys Vice President, Finance and Administration, effective June 28, 2024. Ms. Heatons resignation is not the result of any disagreement between Ms. Heaton and the Company, its management or board of directors, or related to the Companys operations, policies or practices. On June 24, 2024, the Companys Board of Directors appointed Jeffrey Bonacorda as its Principal Accounting Officer and Principal Financial Officer, effective July 1, 2024. Mr. Bonacordas annual base compensation will be $150,000. Mr. Bonacorda joined Kazia on May 13, 2024 and currently serves as the Companys Vice President, Finance and Controller. Mr Bonacorda is a senior accounting professional with more than 25 years of experience in the commercial pharmaceutical, consumer products and service industries. The Company hereby incorporates by reference the information contained herein into the Companys registration statements on Form F-3 (File Nos. 333-259224 and 333-276091). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therape utics Limited (Registrant) /s/ John Friend John Friend Chief Executive Officer Date: 24 June 2024

View Full Filing

View this 6-K filing on SEC EDGAR